Table 3

HRs for discontinuing a first ever TNFi in patients with AS, depending on presence of extra-articular SpA manifestations, adjusted for baseline characteristics, comorbidities and socioeconomic factors

Extra-articular SpA manifestationsBase model* Comorbidity model†Socioeconomic model‡Full model§
Anterior uveitis, 0–1.5 years of follow-up0.57 (0.46–0.70)0.58 (0.47–0.72)0.61 (0.49–0.77)0.62 (0.49–0.78)
Anterior uveitis, >1.5 years of follow-up1.10 (0.83–1.45)1.09 (0.82–1.43)1.17 (0.87–1.58)1.17 (0.87–1.57)
Psoriasis1.35 (1.04–1.76)1.28 (0.98–1.67)1.36 (0.01–1.82)1.31 (0.97–1.76)
IBD0.84 (0.65–1.09)0.82 (0.63–1.07)0.83 (0.62–1.10)0.84 (0.63–1.13)
  • *Base model adjusted for baseline characteristics: age, sex, C-reactive protein, peripheral arthritis, Bath Ankylosing Spondylitis Disease Activity Index and type of tumour necrosis factor alpha inhibitorTNFi.

  • †Comorbidity model adjusted for the same covariates as the base model, and in addition for the presence of each of the chronicconcurrent comorbidities: cardiovascular disease, affective disorders, chronic lung disease, diabetes, chronic kidney diseaseand for a history of a malignancy.

  • ‡Socioeconomic model adjusted for the same covariates as the base model, and in addition for annual household income, sick leave/disability pension rate, level of formal education and country of origin.

  • §Full model adjusted for all of the above-mentioned covariates.

  • AS, ankylosing spondylitis; IBD, inflammatory bowel disease; SpA, spondyloarthritis; TNFi, tumour necrosis factor alpha inhibitor.